-
Document de presse | 2005.11.27
Glaxosmithkline Biologicals Licenses Institut Pasteur Technology to develop AIDS Vaccine; Innovative Public-Private Partenership will use Measles Vaccine As starting point
Using an ancient scourge to combat a new one, researchers from GlaxoSmithKline Biologicals and the Institut Pasteur announced a new European collaboration to develop an AIDS vaccine by fusing genes from the human immunodeficiency virus (HIV) onto an existing measles vaccine. Press release Paris, november 28, 2005 GSK Biologicals will license the measles vaccine vector...
-
Article | 2020.06.22
Development of novel nano-based multi-epitope vaccine against coronavirus SARS-CoV-2 - Generation of Humanized NSG transfer mouse model for vaccine testing
Aim: We hypothesize that it may be possible to generate protective anti-SARS-CoV-2 immuneresponse in humanized NSG transfer mouse model. This will be achieved by administering to them of lipid-based nanoparticles carrying peptide molecules, comprising dominant immunogenic B and T cell epitopes from coronavirus SARS-CoV-2. The epitopes will be predicted by EpiDOCK server for evaluation of...
-
News | 2025.08.27
Discover the Pasteur Institute's major discoveries for 2024
A gene therapy trial for childhood deafness. A malaria vaccine. Microbiome gene editing. Cancer immunotherapy. A key gene in embryonic development. Effective treatment for bronchiolitis. Indian Ocean temperatures for anticipating outbreaks... Here is an excerpt from our discoveries for 2024. You can also download the poster in PDF format at the bottom of the page.
-
News | 2023.07.24
Rabies: elucidating the disease to limit spread and prepare for future outbreaks
Although rabies control has progressed considerably since Louis Pasteur first trialed his vaccine, the disease continues to kill thousands of people who do not have access to treatment. Scientists have traced the evolution of the disease worldwide over different eras in a bid to improve our understanding of and preparedness for emerging infectious diseases.
-
News | 2022.05.12
SARS-CoV 2: A booster with a "Lenti-COVID" vaccine candidate induces protective immunity in the respiratory mucosa in a preclinical model
Scientist at the Institut Pasteur- TheraVectys Joint Laboratory have demonstrated the efficacy of their lentiviral candidate vaccine “Lenti-COVID”, administered as an intranasal booster dose six months after primary vaccination with a messenger RNA vaccine, in a pre-clinical model. This intranasal booster induces protective immunity in the respiratory mucosa. These results pave the way for...
-
Document de presse | 2020.05.26
MV-SARS-CoV-2 vaccine candidate: a new partnership between Institut Pasteur, CEPI, Thémis and MSD
Institut Pasteur announces recent advances in the development of one of its candidate vaccines, MV-SARS-CoV-2, using the measles vector, as part of a renewed partnership with CEPI and the companies Thémis and MSD.With over 100 vaccine projects in development worldwide, the development of a vaccine against SARS CoV-2 infection remains a challenge, with many scientific uncertainties ahead. The...
-
Document de presse | 2021.01.25
COVID-19: progress update on the Institut Pasteur's scientific response and vaccine candidate research programs
Since early 2020, the Institut Pasteur has been engaged in research in several of its areas of scientific expertise, including virology, diagnostics, pathophysiology, epidemiology, modeling, therapeutic research and vaccine research. A number of research programs to find a vaccine for SARS-CoV-2, the virus responsible for the COVID-19 epidemic, are under way. In light of the intermediate results...
-
Document de presse | 2015.03.01
Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases
Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability. Themis Bioscience (‘Themis’), a biotechnology company developing innovative prophylactic vaccines for emerging tropical infections, and the Institut Pasteur, an international...
-
Document de presse | 2014.11.19
A major step forward in fight against Chikungunya fever: Themis Bioscience’s vaccine candidate successful in phase 1
Results presented at international conferences in Philadelphia and in New Orleans. The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate was...
-
Document de presse | 2005.06.27
Gates millions for vaccine research The fight against hepatitis C and HIV: foundation supports international consortium
The Bill and Melinda Gates Foundation (Seattle, USA) has decided to fund an international research consortium led by the German Research Centre of Biotechnology (GBF) in Braunschweig and the Institut Pasteur in Paris. The long-term goal of the 9 million dollar project is the development of vaccines against Hepatitis C and HIV. Press release Paris, june 28, 2005 “...